Nov 20 (Reuters) - Drug delivery systems maker Delcath Systems Inc (DCTH.O: Quote, Profile, Research) said U.S. health regulators allowed the company to resume patient enrollment in the late- and mid-stage trials of its system used in the treatment of certain liver cancers, sending shares up 47 percent.
